(VNRX) Volitionrx - Ratings and Ratios
Exchange: NYSE MKT • Country: United States • Currency: USD • Type: Common Stock • ISIN: US9286611077
VNRX: Cancer, Sepsis, COVID-19, Diagnostic, Blood, Tests
VolitionRx Limited, a multi-national epigenetics company, specializes in developing innovative blood-based tests for the diagnosis and monitoring of various cancers, sepsis, and COVID-19. Leveraging its expertise in nucleosome technology, the company has developed a suite of products aimed at improving disease detection and management. Its product portfolio includes Nu.Q Vet, a cancer screening test designed for veterinary use in dogs and other animals; Nu.Q Nets, which monitors immune system activity; Nu.Q Cancer, a tool for tracking disease progression, treatment response, and minimal residual disease; Capture-PCR, a method for isolating and capturing circulating tumor-derived DNA from plasma samples to enhance early cancer detection; and Nu.Q Discover, a solution for nucleosome profiling. Headquartered in Henderson, Nevada, VolitionRx operates globally, advancing its mission to transform disease diagnosis through epigenetic innovation.
Based on the provided technical and fundamental data, the 3-month forecast for VolitionRx Limited (NYSE MKT: VNRX) suggests a challenging period ahead. Technically, the stock is trading below its 20-day, 50-day, and 200-day moving averages, indicating bearish momentum. The average true range (ATR) of 0.04 reflects low volatility, suggesting limited price movement. Fundamentally, the companys high price-to-book (P/B) ratio of 38.44 and price-to-sales (P/S) ratio of 46.27 highlight a rich valuation, driven by growth expectations rather than current profitability. The return on equity (RoE) of 138.92% underscores efficient equity utilization. However, with a market capitalization of $59.50M and no forward P/E, the stock may face pressure from high valuation multiples and the absence of profitability. Overall, the technical outlook remains bearish, with potential downside risks in the near term.
Additional Sources for VNRX Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
VNRX Stock Overview
Market Cap in USD | 58m |
Sector | Healthcare |
Industry | Medical Devices |
GiC Sub-Industry | Health Care Supplies |
IPO / Inception | 2007-04-25 |
VNRX Stock Ratings
Growth 5y | -83.6% |
Fundamental | 32.0% |
Dividend | 0.0% |
Rel. Strength Industry | -38.2 |
Analysts | 4.33/5 |
Fair Price Momentum | 0.38 USD |
Fair Price DCF | - |
VNRX Dividends
No Dividends PaidVNRX Growth Ratios
Growth Correlation 3m | -48% |
Growth Correlation 12m | -59.1% |
Growth Correlation 5y | -94.1% |
CAGR 5y | -25.62% |
CAGR/Max DD 5y | -0.28 |
Sharpe Ratio 12m | -0.04 |
Alpha | -50.79 |
Beta | 1.38 |
Volatility | 78.06% |
Current Volume | 40.5k |
Average Volume 20d | 104.7k |
As of March 16, 2025, the stock is trading at USD 0.56 with a total of 40,502 shares traded.
Over the past week, the price has changed by -8.02%, over one month by -10.94%, over three months by -9.50% and over the past year by -37.66%.
Neither. Based on ValueRay Fundamental Analyses, Volitionrx is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 31.97 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of VNRX as of March 2025 is 0.38. This means that VNRX is currently overvalued and has a potential downside of -32.14%.
Volitionrx has received a consensus analysts rating of 4.33. Therefor, it is recommend to buy VNRX.
- Strong Buy: 2
- Buy: 0
- Hold: 1
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, VNRX Volitionrx will be worth about 0.4 in March 2026. The stock is currently trading at 0.56. This means that the stock has a potential downside of -23.21%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 3.4 | 501.8% |
Analysts Target Price | 3.3 | 496.4% |
ValueRay Target Price | 0.4 | -23.2% |